asp7962
Osteoarthritis of the Knee
Astellas Pharma Europe B.V.Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Osteoarthritis of the Knee cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
tlc599 Taiwan Liposome Company | Phase 3 | BB |
Duloxetine Eli Lilly and Company | Phase 3 | BB |
Buprenorphine Purdue Pharma LP | Phase 3 | B |
DEXAMETHASONE Taiwan Liposome Company | Phase 3 | B |
Nktr-181 Nektar Therapeutics | Phase 2 | B |
View all 9 →
Same molecule, other indications
asp7962 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →